Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 255

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA

Open access
Vellas, B., Gillette-Guyonnet, S., Touchon, J., Dantoine, T., Dartigues, J.F., Cuffi, M.N., Bordes, S., Gasnier, Y., Robert, P., Bories, L., Rouaud, O., Desclaux, F., Sudres, K., Bonnefoy, M., Pesce, A., Dufouil, C., Lehericy, S., Chupin, M., Mangin, J.F., Payoux, P., Adel, D., Legrand, P., Catheline, D., Kanony, C., Zaim, M., Molinier, L., Costa, N., Delrieu, J., Voisin, T., Faisant, C., Lala, F., Nourhashemi, F., Rolland, Y., Abellan Van Kan, G., Dupuy, C., Cantet, C., Cestac, P., Belleville, S., Willis, S., Cesari, M., Weiner, M.W., Soto, M.E., Ousset, P.J., Andrieu, S., Carrie, I. · 2014 · The Journal Of Prevention of Alzheimer's Disease

Abstract

Objective: The Multidomain Alzheimer Preventive Trial (MAPT study) was designed to assess the efficacy of isolated supplementation with omega-3 fatty acid, an isolated multidomain intervention (consisting of nutritional counseling, physical exercise, cognitive stimulation) or a combination of the two interventions on the change of cognitive functions in frail subjects aged 70 years and older for a period of 3 years. Ancillary neuroimaging studies were additionally implemented to evaluate the impact of interventions on cerebral metabolism (FDG PET scans) and atrophy rate (MRIs), as well as brain amyloïd deposit (AV45 PET scans). Design, patients: 1680 subjects (mean age: 75.3 years; female: 64.8 %), enrolled by 13 memory clinics, were randomized into one of the following four groups: omega-3 supplementation alone, multidomain intervention alone, omega-3 plus multidomain intervention, or placebo. Participants underwent cognitive, functional and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint is a change of memory function at 3 years, as assessed by the Free and Cued Selective Reminding test. All participants will be followed for 2 additional years after the 3-years intervention (MAPT PLUS extension study). Interventions: 1/ Omega-3 supplementation: two soft capsules daily as a single dose, containing a total of 400 mg docosahexaenoic acid (DHA), i.e., 800 mg docosahexaenoic acid per day, for 3 years. 2/ Multidomain intervention: collective training sessions conducted in small groups (6–8 participants) in twelve 120-minute sessions over the first 2 months (two sessions a week for the first month, and one session a week the second month) then a 60-minute session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. In addition to the collective sessions, individualized preventive outpatient visits exploring possible risk factors for cognitive decline are performed at baseline, M12 and M24. Baseline population: For cognition, the mean MMSE at baseline was 28.1 (± 1.6). About 58% and 42% of participants had a CDR score equal to 0 and 0.5, respectively. Regarding mobility status, 200 (11.9%) had a 4-m gait speed lower or equal to 0.8 m/s. According to the Fried criteria, 673 (42.1%) participants were considered pre frail, and 51 (3.2%) frail. The red blood cell DHA content was 26.1 ± 8.1 µg/g. Five hundred and three participants underwent baseline MRI. AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. Discussion: The MAPT trial is presently the first largest and longest multidomain preventive trial relevant to cognitive decline in older adults with subjective memory complaints. The multidomain intervention designed for the MAPT trial is likely to be easily implemented within the general population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jpad.2014.34

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 255

Metadata

Authors
Vellas, B., Gillette-Guyonnet, S., Touchon, J., Dantoine, T., Dartigues, J. F., Cuffi, M. N., Bordes, S., Gasnier, Y., Robert, P., Bories, L., Rouaud, O., Desclaux, F., Sudres, K., Bonnefoy, M., Pesce, A., Dufouil, C., Lehericy, S., Chupin, M., Mangin, J. F., Payoux, P., Adel, D., Legrand, P., Catheline, D., Kanony, C., Zaim, M., Molinier, L., Costa, N., Delrieu, J., Voisin, T., Faisant, C., Lala, F., Nourhashemi, F., Rolland, Y., Abellan Van Kan, G., Dupuy, C., Cantet, C., Cestac, P., Belleville, S., Willis, S., Cesari, M., Weiner, M. W., Soto, M. E., Ousset, P. J., Andrieu, S., & Carrie, I.
Venue
The Journal Of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2014
Volume
1
Issue
1
Pages
1-10
ISSN
2274-5807 (ISSN-L)
OpenAlex
W2183174223
Cited by
255
References
63
FWCI
13.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA. https://app.cochat.ai/papers/10.14283/jpad.2014.34
The paper
Vellas, B., Gillette-Guyonnet, S., Touchon, J., Dantoine, T., Dartigues, J. F., Cuffi, M. N., Bordes, S., Gasnier, Y., Robert, P., Bories, L., Rouaud, O., Desclaux, F., Sudres, K., Bonnefoy, M., Pesce, A., Dufouil, C., Lehericy, S., Chupin, M., Mangin, J. F., . . . Carrie, I. (2014). MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA. The Journal Of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2014.34

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.